Free Trial

Best Penny Stocks Under $1.00 Right Now

The stock market has had an incredible bull-run since the Great Recession of 2008 and 2009. While stocks are no longer hitting new all-time highs, the price-to-earnings ratios of most S&P 500 companies still look somewhat expensive historically speaking. Many investors are having trouble finding low-priced stocks that have great business fundamentals and actually generate cash flow.

Stocks have gotten expensive both in-terms of share price and their valuation relative to earnings. In more normal markets, a typical S&P 500 company has traded at about fifteen times their earnings. Most stocks are currently trading closer to 20 times their annual earnings. While the stock market is more expensive as a whole than it has been historically, there are still a handful of undervalued stocks that are trading at less than $1.00 per share.

Value investing opportunities do exist if you're looking in the right places. Putting together a list of the best stocks under $1.00 requires investors to look at smaller and riskier companies and in sectors that are either undiscovered or unloved by the market as a whole. Some of these cheap stocks may not look especially attractive today, but long-term investors will profit if they are willing to exercise patience and hold on to shares of these companies through multiple economic cycles.

Some of these companies are solid investing ideas because they are too little and considered too risky to attract the interest of most managed mutual funds and Wall Street money managers. Others operate in unloved and untested areas of the market. You may find even find crypto stocks, marijuana stocks, and biotechnology stocks on this list. Others have been beat up by Mr. Market after a long period of slowing profits, but are now actively trying to turn around their business and bounce back. These low-priced stocks operate in a lot of different industries, but these picks all carry two common characteristics. They all have a super-low share price of $1.00 (1 dollar) or less and consistently-receive "buy" and "strong buy" ratings from Wall Street's top-rated research analysts.

Reviva Pharmaceuticals stock logo

1. Reviva Pharmaceuticals NASDAQ:RVPH

$0.44 -0.03 (-6.90%)
Closing price 04:00 PM Eastern
Extended Trading
$0.44 +0.00 (+0.78%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. More about Reviva Pharmaceuticals

Market Capitalization
$22.46 million
P/E Ratio
-0.55
Consensus Rating
Buy
Consensus Price Target
$9.00 (+1,966.1% Upside)
Volume
1.75 million shares
Average Volume
2.97 million shares
Immunic stock logo

2. Immunic NASDAQ:IMUX

$0.93 -0.01 (-0.91%)
Closing price 04:00 PM Eastern
Extended Trading
$0.94 +0.01 (+0.81%)
As of 07:23 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. More about Immunic

Market Capitalization
$90.08 million
P/E Ratio
-0.76
Consensus Rating
Buy
Consensus Price Target
$7.50 (+705.2% Upside)
Volume
668,229 shares
Average Volume
1.07 million shares
Ovid Therapeutics stock logo

3. Ovid Therapeutics NASDAQ:OVID

$0.50 0.00 (0.00%)
Closing price 04:00 PM Eastern
Extended Trading
$0.50 +0.00 (+0.60%)
As of 07:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Ovid Therapeutics Inc, a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. More about Ovid Therapeutics

Market Capitalization
$35.56 million
P/E Ratio
-1.43
Consensus Rating
Buy
Consensus Price Target
$3.13 (+525.0% Upside)
Volume
535,545 shares
Average Volume
2.52 million shares
FibroBiologics stock logo

4. FibroBiologics NASDAQ:FBLG

$0.65 +0.01 (+1.82%)
Closing price 04:00 PM Eastern
Extended Trading
$0.64 -0.01 (-1.17%)
As of 07:24 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

FibroBiologics, Inc operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. More about FibroBiologics

Market Capitalization
$25.28 million
P/E Ratio
-1.80
Consensus Rating
Buy
Consensus Price Target
$13.00 (+1,904.3% Upside)
Volume
746,797 shares
Average Volume
458,093 shares
Stardust Power stock logo

5. Stardust Power NASDAQ:SDST

$0.41 -0.01 (-2.32%)
Closing price 04:00 PM Eastern
Extended Trading
$0.40 -0.01 (-1.65%)
As of 07:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Stardust Power Inc is a vertically-integrated lithium refinery that engages in producing battery-grade lithium. The company was founded in 2022 and is based in Greenwich, Connecticut.

Market Capitalization
$25.63 million
P/E Ratio
-0.56
Consensus Rating
Buy
Consensus Price Target
$5.11 (+1,141.5% Upside)
Volume
1.33 million shares
Average Volume
25.72 million shares
Context Therapeutics stock logo

6. Context Therapeutics NASDAQ:CNTX

$0.71 -0.02 (-2.74%)
Closing price 04:00 PM Eastern
Extended Trading
$0.71 +0.00 (+0.28%)
As of 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. More about Context Therapeutics

Market Capitalization
$65.48 million
P/E Ratio
-2.29
Consensus Rating
Buy
Consensus Price Target
$5.50 (+674.6% Upside)
Volume
119,312 shares
Average Volume
196,248 shares
Adicet Bio stock logo

7. Adicet Bio NASDAQ:ACET

$0.67 -0.02 (-2.19%)
Closing price 04:00 PM Eastern
Extended Trading
$0.70 +0.03 (+4.53%)
As of 07:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Adicet Bio, Inc, a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. More about Adicet Bio

Market Capitalization
$56.71 million
P/E Ratio
-0.52
Consensus Rating
Buy
Consensus Price Target
$6.00 (+794.7% Upside)
Volume
271,773 shares
Average Volume
355,689 shares
Tenaya Therapeutics stock logo

8. Tenaya Therapeutics NASDAQ:TNYA

$0.67 -0.01 (-0.80%)
Closing price 04:00 PM Eastern
Extended Trading
$0.68 +0.01 (+1.25%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. More about Tenaya Therapeutics

Market Capitalization
$109.96 million
P/E Ratio
-0.58
Consensus Rating
Buy
Consensus Price Target
$6.25 (+832.0% Upside)
Volume
1.57 million shares
Average Volume
2.36 million shares
InflaRx stock logo

9. InflaRx NASDAQ:IFRX

$0.86 -0.05 (-4.97%)
Closing price 04:00 PM Eastern
Extended Trading
$0.86 +0.00 (+0.12%)
As of 04:15 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. More about InflaRx

Market Capitalization
$60.76 million
P/E Ratio
-1.05
Consensus Rating
Buy
Consensus Price Target
$6.60 (+667.4% Upside)
Volume
123,610 shares
Average Volume
368,745 shares
FiscalNote stock logo

10. FiscalNote NYSE:NOTE

$0.56 0.00 (-0.51%)
Closing price 03:59 PM Eastern
Extended Trading
$0.59 +0.02 (+3.97%)
As of 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

FiscalNote Holdings, Inc operates as technology company North America, Europe, Australia, and Asia. It combines artificial intelligence technology, machine learning, and other technologies with analytics, workflow tools, and expert research. More about FiscalNote

Market Capitalization
$89.63 million
P/E Ratio
-1.71
Consensus Rating
Buy
Consensus Price Target
$2.63 (+367.2% Upside)
Volume
1.91 million shares
Average Volume
2.74 million shares
Lineage Cell Therapeutics stock logo

11. Lineage Cell Therapeutics NYSEAMERICAN:LCTX

$0.99 -0.03 (-3.40%)
Closing price 04:10 PM Eastern
Extended Trading
$1.00 +0.02 (+1.80%)
As of 07:29 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. More about Lineage Cell Therapeutics

Market Capitalization
$232.92 million
P/E Ratio
-12.32
Consensus Rating
Buy
Consensus Price Target
$4.20 (+326.3% Upside)
Volume
2.00 million shares
Average Volume
1.55 million shares
Cresco Labs stock logo

12. Cresco Labs OTCMKTS:CRLBF

$0.62 +0.03 (+4.48%)
As of 03:59 PM Eastern

Cresco Labs Inc, together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States. More about Cresco Labs

Market Capitalization
$291.37 million
P/E Ratio
-2.58
Consensus Rating
Buy
Volume
1.30 million shares
Average Volume
798,477 shares
Today's Range
$0.57
$0.66
Century Therapeutics stock logo

13. Century Therapeutics NASDAQ:IPSC

$0.53 -0.02 (-2.87%)
Closing price 04:00 PM Eastern
Extended Trading
$0.53 +0.00 (+0.21%)
As of 07:26 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. More about Century Therapeutics

Market Capitalization
$47.18 million
P/E Ratio
-1.83
Consensus Rating
Buy
Consensus Price Target
$4.20 (+689.6% Upside)
Volume
710,670 shares
Average Volume
1.05 million shares
ALX Oncology stock logo

14. ALX Oncology NASDAQ:ALXO

$0.52 -0.05 (-8.70%)
Closing price 04:00 PM Eastern
Extended Trading
$0.53 +0.01 (+1.91%)
As of 05:31 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. More about ALX Oncology

Market Capitalization
$30.30 million
P/E Ratio
-0.21
Consensus Rating
Moderate Buy
Consensus Price Target
$3.30 (+536.9% Upside)
Volume
415,913 shares
Average Volume
520,729 shares
i-80 Gold stock logo

15. i-80 Gold NYSE:IAUX

$0.56 +0.00 (+0.61%)
Closing price 04:00 PM Eastern
Extended Trading
$0.58 +0.01 (+2.16%)
As of 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

i-80 Gold Corp. is a mining company, engages in the exploration, development and production of gold and silver mineral deposits principally in the United States. More about i-80 Gold

Market Capitalization
$444.34 million
P/E Ratio
-1.57
Consensus Rating
Moderate Buy
Consensus Price Target
$1.50 (+166.1% Upside)
Volume
3.15 million shares
Average Volume
6.02 million shares
Shattuck Labs stock logo

16. Shattuck Labs NASDAQ:STTK

$0.75 -0.01 (-1.52%)
As of 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. More about Shattuck Labs

Market Capitalization
$36.48 million
P/E Ratio
-0.53
Consensus Rating
Moderate Buy
Consensus Price Target
$7.50 (+924.6% Upside)
Volume
79,399 shares
Average Volume
208,395 shares
Omega Therapeutics stock logo

17. Omega Therapeutics OTCMKTS:OMGAQ

$0.02 0.00 (-12.20%)
As of 11:44 AM Eastern

Omega Therapeutics, Inc operates as a clinical-stage biotechnology company. The company's OMEGA platform enables control of fundamental epigenetic processes to correct the root cause of disease by restoring aberrant gene expression to a range without altering native nucleic acid sequences. More about Omega Therapeutics

Market Capitalization
$1.13 million
P/E Ratio
-0.01
Consensus Rating
Moderate Buy
Consensus Price Target
$8.50 (+47,122.2% Upside)
Volume
541 shares
Average Volume
470,796 shares
Biodesix stock logo

18. Biodesix NASDAQ:BDSX

$0.36 +0.01 (+3.27%)
Closing price 04:00 PM Eastern
Extended Trading
$0.36 0.00 (-0.61%)
As of 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Biodesix, Inc operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. More about Biodesix

Market Capitalization
$51.55 million
P/E Ratio
-1.25
Consensus Rating
Moderate Buy
Consensus Price Target
$1.75 (+381.8% Upside)
Volume
469,857 shares
Average Volume
1.09 million shares
Oncolytics Biotech stock logo

19. Oncolytics Biotech NASDAQ:ONCY

$0.99 -0.03 (-2.94%)
Closing price 04:00 PM Eastern
Extended Trading
$1.00 +0.01 (+1.52%)
As of 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. More about Oncolytics Biotech

Market Capitalization
$99.36 million
P/E Ratio
-3.41
Consensus Rating
Moderate Buy
Consensus Price Target
$4.33 (+337.7% Upside)
Volume
537,614 shares
Average Volume
1.31 million shares
Carisma Therapeutics stock logo

20. Carisma Therapeutics NASDAQ:CARM

$0.31 -0.01 (-3.26%)
Closing price 04:00 PM Eastern
Extended Trading
$0.31 0.00 (-1.44%)
As of 07:32 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Carisma Therapeutics, Inc, a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. More about Carisma Therapeutics

Market Capitalization
$13.46 million
P/E Ratio
-0.20
Consensus Rating
Moderate Buy
Consensus Price Target
$1.93 (+518.0% Upside)
Volume
357,487 shares
Average Volume
612,275 shares
Sangamo Therapeutics stock logo

21. Sangamo Therapeutics NASDAQ:SGMO

$0.56 +0.02 (+4.56%)
Closing price 04:00 PM Eastern
Extended Trading
$0.56 0.00 (-0.28%)
As of 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. More about Sangamo Therapeutics

Market Capitalization
$125.23 million
P/E Ratio
-1.44
Consensus Rating
Moderate Buy
Consensus Price Target
$4.50 (+701.3% Upside)
Volume
4.20 million shares
Average Volume
5.73 million shares
Canaan stock logo

22. Canaan NASDAQ:CAN

$0.66 -0.03 (-4.53%)
Closing price 04:00 PM Eastern
Extended Trading
$0.66 0.00 (-0.62%)
As of 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Canaan Inc engages in the research, design, and sale of integrated circuit (IC) final mining equipment products by integrating IC products for bitcoin mining and related components in the People's Republic of China. More about Canaan

Market Capitalization
$257.45 million
P/E Ratio
-0.65
Consensus Rating
Moderate Buy
Consensus Price Target
$2.67 (+304.6% Upside)
Volume
49.10 million shares
Average Volume
55.80 million shares
Applied Therapeutics stock logo

23. Applied Therapeutics NASDAQ:APLT

$0.44 -0.01 (-2.07%)
Closing price 04:00 PM Eastern
Extended Trading
$0.44 +0.00 (+0.52%)
As of 07:32 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Applied Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. More about Applied Therapeutics

Market Capitalization
$63.71 million
P/E Ratio
-1.02
Consensus Rating
Moderate Buy
Consensus Price Target
$6.10 (+1,284.2% Upside)
Volume
673,519 shares
Average Volume
1.57 million shares
Blink Charging stock logo

24. Blink Charging NASDAQ:BLNK

$0.95 -0.02 (-2.31%)
Closing price 04:00 PM Eastern
Extended Trading
$0.96 +0.01 (+0.54%)
As of 07:40 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Blink Charging Co, through its subsidiaries, owns, operates, manufactures, and provides electric vehicle (EV) charging equipment and networked EV charging services in the United States and internationally. More about Blink Charging

Market Capitalization
$99.99 million
P/E Ratio
-0.48
Consensus Rating
Hold
Consensus Price Target
$2.40 (+152.4% Upside)
Volume
1.38 million shares
Average Volume
2.98 million shares
Sutro Biopharma stock logo

25. Sutro Biopharma NASDAQ:STRO

$0.81 +0.00 (+0.58%)
Closing price 04:00 PM Eastern
Extended Trading
$0.80 -0.01 (-1.48%)
As of 05:33 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Sutro Biopharma, Inc operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. More about Sutro Biopharma

Market Capitalization
$68.02 million
P/E Ratio
-0.27
Consensus Rating
Hold
Consensus Price Target
$6.11 (+654.9% Upside)
Volume
233,544 shares
Average Volume
483,404 shares